To validate whether targeting METTL3 in osteoblasts could inhibit the progression of senile osteoporosis, osteoblast-specific AAV9-METTL3 was administered via tail vein injection to 20-week-old C57BL/6 J mice (Fig. 6a, Supplementary Fig. 2f). Here, METTL3 is linked to osteoporosis.